Effects of Rostafuroxin on Blood Pressure in Hypertension
Author Information
Author(s): Jan A Staessen, Lutgarde Thijs, Katarzyna Stolarz-Skrzypek, Antonella Bacchieri, John Barton, Ezio degli Espositi, Peter W de Leeuw, Mirosław Dłużniewski, Nicola Glorioso, Andrzej Januszewicz, Paolo Manunta, Viktor Milyagin, Yuri Nikitin, Miroslav Souček, Chiara Lanzani, Lorena Citterio, Mario Timio, Andrzej Tykarski, Patrizia Ferrari, Giovanni Valentini, Kalina Kawecka-Jaszcz, Giuseppe Bianchi
Primary Institution: University of Leuven
Hypothesis
Does rostafuroxin significantly reduce blood pressure in patients with uncomplicated hypertension compared to placebo?
Conclusion
Rostafuroxin did not reduce blood pressure at any dose in the study.
Supporting Evidence
- Rostafuroxin did not show significant blood pressure reduction compared to placebo.
- Minor side effects were reported with similar frequency in both treatment groups.
- Only 51.6% of patients maintained a 24-h urinary sodium excretion below 200 mmol.
Takeaway
The study tested a new medicine called rostafuroxin to see if it could help lower blood pressure, but it didn't work.
Methodology
The study was a phase-2 double-blind, placebo-controlled trial with 5 concurrent cross-over studies involving 435 patients.
Potential Biases
Potential bias due to the inclusion of patients previously treated for hypertension.
Limitations
The study included previously treated patients, which may have affected the results.
Participant Demographics
Mean age was 48.4 years, with 40.5% women.
Statistical Information
P-Value
P = 0.03
Confidence Interval
95% CI, 0.10 to 2.50
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website